178 related articles for article (PubMed ID: 27931902)
1. Effectiveness of blonanserin for patients with drug treatment-resistant schizophrenia and dopamine supersensitivity: A retrospective analysis.
Tachibana M; Niitsu T; Watanabe M; Hashimoto T; Kanahara N; Ishikawa M; Iyo M
Asian J Psychiatr; 2016 Dec; 24():28-32. PubMed ID: 27931902
[TBL] [Abstract][Full Text] [Related]
2. A prospective comparative study of risperidone long-acting injectable for treatment-resistant schizophrenia with dopamine supersensitivity psychosis.
Kimura H; Kanahara N; Komatsu N; Ishige M; Muneoka K; Yoshimura M; Yamanaka H; Suzuki T; Komatsu H; Sasaki T; Hashimoto T; Hasegawa T; Shiina A; Ishikawa M; Sekine Y; Shiraishi T; Watanabe H; Shimizu E; Hashimoto K; Iyo M
Schizophr Res; 2014 May; 155(1-3):52-8. PubMed ID: 24667073
[TBL] [Abstract][Full Text] [Related]
3. A randomized-controlled trial of blonanserin and olanzapine as adjunct to antipsychotics in the treatment of patients with schizophrenia and dopamine supersensitivity psychosis: The ROADS study.
Niitsu T; Hata T; Nishimoto M; Hosoda Y; Kimura A; Oda Y; Suzuki M; Takase N; Seki R; Fujita K; Endo M; Yoshida T; Inoue M; Hattori N; Murakami T; Imamura Y; Ogawa K; Fukami G; Sato T; Kawasaki Y; Hashimoto T; Ishikawa M; Shiina A; Kanahara N; Iyo M;
Asian J Psychiatr; 2020 Oct; 53():102369. PubMed ID: 32920492
[TBL] [Abstract][Full Text] [Related]
4. Blonanserin vs risperidone in Japanese patients with schizophrenia: A post hoc analysis of a phase 3, 8-week, multicenter, double-blind, randomized controlled study.
Harvey PD; Nakamura H; Miura S
Neuropsychopharmacol Rep; 2020 Mar; 40(1):63-72. PubMed ID: 31788985
[TBL] [Abstract][Full Text] [Related]
5. Risperidone long-acting injectable in the treatment of treatment-resistant schizophrenia with dopamine supersensitivity psychosis: Results of a 2-year prospective study, including an additional 1-year follow-up.
Kimura H; Kanahara N; Sasaki T; Komatsu N; Ishige M; Muneoka K; Ino H; Yoshimura K; Yamanaka H; Suzuki T; Komatsu H; Watanabe H; Shimizu E; Iyo M
J Psychopharmacol; 2016 Aug; 30(8):795-802. PubMed ID: 27371496
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of blonanserin transdermal patch in patients with schizophrenia: A 6-week randomized, double-blind, placebo-controlled, multicenter study.
Iwata N; Ishigooka J; Kim WH; Yoon BH; Lin SK; Sulaiman AH; Cosca R; Wang L; Suchkov Y; Agarkov A; Watabe K; Matsui T; Sato T; Inoue Y; Higuchi T; Correll CU; Kane JM
Schizophr Res; 2020 Jan; 215():408-415. PubMed ID: 31471246
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy and safety of blonanserin in patients with first-episode schizophrenia: a 1-year open-label trial.
Ninomiya Y; Miyamoto S; Tenjin T; Ogino S; Miyake N; Kaneda Y; Sumiyoshi T; Yamaguchi N
Psychiatry Clin Neurosci; 2014 Dec; 68(12):841-849. PubMed ID: 24835911
[TBL] [Abstract][Full Text] [Related]
8. Effect of blonanserin on cognitive function in antipsychotic-naïve first-episode schizophrenia.
Tenjin T; Miyamoto S; Miyake N; Ogino S; Kitajima R; Ojima K; Arai J; Teramoto H; Tsukahara S; Ito Y; Tadokoro M; Anai K; Funamoto Y; Kaneda Y; Sumiyoshi T; Yamaguchi N
Hum Psychopharmacol; 2012 Jan; 27(1):90-100. PubMed ID: 22278973
[TBL] [Abstract][Full Text] [Related]
9. Safety and effectiveness of oral blonanserin for schizophrenia: A review of Japanese post-marketing surveillances.
Inoue Y; Tsuchimori K; Nakamura H
J Pharmacol Sci; 2021 Jan; 145(1):42-51. PubMed ID: 33357778
[TBL] [Abstract][Full Text] [Related]
10. Defining treatment-resistant schizophrenia and response to antipsychotics: a review and recommendation.
Suzuki T; Remington G; Mulsant BH; Uchida H; Rajji TK; Graff-Guerrero A; Mimura M; Mamo DC
Psychiatry Res; 2012 May; 197(1-2):1-6. PubMed ID: 22429484
[TBL] [Abstract][Full Text] [Related]
11. Impact of dopamine supersensitivity psychosis in treatment-resistant schizophrenia: An analysis of multi-factors predicting long-term prognosis.
Yamanaka H; Kanahara N; Suzuki T; Takase M; Moriyama T; Watanabe H; Hirata T; Asano M; Iyo M
Schizophr Res; 2016 Feb; 170(2-3):252-8. PubMed ID: 26775264
[TBL] [Abstract][Full Text] [Related]
12. Striatal and extrastriatal dopamine D2 receptor occupancy by a novel antipsychotic, blonanserin: a PET study with [11C]raclopride and [11C]FLB 457 in schizophrenia.
Tateno A; Arakawa R; Okumura M; Fukuta H; Honjo K; Ishihara K; Nakamura H; Kumita S; Okubo Y
J Clin Psychopharmacol; 2013 Apr; 33(2):162-9. PubMed ID: 23422369
[TBL] [Abstract][Full Text] [Related]
13. Switching antipsychotics to aripiprazole or blonanserin and plasma monoamine metabolites levels in patients with schizophrenia.
Miura I; Shiga T; Katsumi A; Kanno-Nozaki K; Mashiko H; Niwa S; Yabe H
Hum Psychopharmacol; 2014 Mar; 29(2):199-202. PubMed ID: 24590545
[TBL] [Abstract][Full Text] [Related]
14. Dopamine supersensitivity psychosis as a pivotal factor in treatment-resistant schizophrenia.
Suzuki T; Kanahara N; Yamanaka H; Takase M; Kimura H; Watanabe H; Iyo M
Psychiatry Res; 2015 Jun; 227(2-3):278-82. PubMed ID: 25863824
[TBL] [Abstract][Full Text] [Related]
15. Striatal Dopamine D2 Receptor Occupancy Induced by Daily Application of Blonanserin Transdermal Patches: Phase II Study in Japanese Patients With Schizophrenia.
Nishibe H; Tateno A; Sakayori T; Yamamoto M; Kim W; Kakuyama H; Okubo Y
Int J Neuropsychopharmacol; 2021 Feb; 24(2):108-117. PubMed ID: 32936897
[TBL] [Abstract][Full Text] [Related]
16. Blonanserin, a novel antipsychotic, is suitable for treating schizophrenia associated with hyperprolactinemia: a case series.
Kawabe K; Horiuchi F; Ueno S
Clin Neuropharmacol; 2013; 36(6):239-41. PubMed ID: 24201238
[TBL] [Abstract][Full Text] [Related]
17. Comparative study of the efficacy and safety between blonanserin and risperidone for the treatment of schizophrenia in Chinese patients: A double-blind, parallel-group multicenter randomized trial.
Li H; Yao C; Shi J; Yang F; Qi S; Wang L; Zhang H; Li J; Wang C; Wang C; Liu C; Li L; Wang Q; Li K; Luo X; Gu N
J Psychiatr Res; 2015 Oct; 69():102-9. PubMed ID: 26343601
[TBL] [Abstract][Full Text] [Related]
18. Atypical antipsychotic properties of blonanserin, a novel dopamine D2 and 5-HT2A antagonist.
Ohno Y; Okano M; Imaki J; Tatara A; Okumura T; Shimizu S
Pharmacol Biochem Behav; 2010 Aug; 96(2):175-80. PubMed ID: 20460137
[TBL] [Abstract][Full Text] [Related]
19. The atypical antipsychotic blonanserin reverses (+)-PD-128907- and ketamine-induced deficit in executive function in common marmosets.
Kotani M; Enomoto T; Murai T; Nakako T; Iwamura Y; Kiyoshi A; Matsumoto K; Matsumoto A; Ikejiri M; Nakayama T; Ogi Y; Ikeda K
Behav Brain Res; 2016 May; 305():212-7. PubMed ID: 26970575
[TBL] [Abstract][Full Text] [Related]
20. [Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics].
Bartkó G; Trixler M; Bitter I; Degrell I; Füredi J; Faludi G;
Neuropsychopharmacol Hung; 2006 Dec; 8(4):201-9. PubMed ID: 17211055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
